One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Active Pharmaceutical Ingredients (API) Global Market

有効成分(API)市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Active Pharmaceutical Ingredients (API) Global Market - Forecast To 2027


Product Code : IQ4IHC00114186
Survey : IQ4I
Publish On : July, 2021
Number of Pages : 703
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
ALBANY MOLECULAR RESEARCH INC
BOEHRINGER INGELHEIM GMBH
DIVIS LABORATORIES
LONZA GROUP
OLON S.P.A
CAMBREX CORPORATION
PFIZER INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
THERMO FISHER SCIENTIFIC
LIST OF COMPANIES MENTIONED IN THE REPORT
AARTI DRUGS LTD.
ABBVIE INC.
ABCELLERA BIOLOGICS INC.
ABCLONAL INC.
ACADIA PHARMACEUTICALS INC.
ACETO
ACIC PHARMACEUTICALS INC.
ADIMMUNE CORPORATION
ADVANCE PHARMACEUTICALS, LLC
AILERON THERAPEUTICS INC.
AJANTA PHARMA LIMITED
AJINOMOTO BIO-PHARMA
ALBEMARLE CORPORATION
ALCAMI CORPORATION, INC.
ALEMBIC PHARMACEUTICALS LTD.
ALKEM LABORATORIES LTD.
ALKERMES PLC
ALMAC GROUP
ALMELO PRIVATE LIMITED
ALPIC REMEDIES LTD.
ALVEN LABORATORIES
AMBIO PHARMA INC.
AMEGA BIOTECH S.A.
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC
AMOYTOP BIOTECH
ANGELINI HOLDING S.P.A.
APROGEN
APUTIT LLC
ARAVIVE INC.
ARENA PHARMACEUTICALS, INC.
AREVIPHARMA GMBH
ARTESAN PHARMA GMBH & CO. KG
ASPIRE LIFESCIENCES PVT., LTD.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
AURINIA PHARMACEUTICALS INC.
AUROBINDO PHARMA LTD.
AVROBIO INC.
AZAD PHARMACEUTICAL INGREDIENTS AG
BACHEM HOLDING AG
BAL PHARMA LTD.
BASF SE
BAXTER INTERNATIONAL INC.
BAYER AG
BIO ELPIDA
BIO GENOMICS LTD.
BIO MARIN PHARMACEUTICALS INC.
BIOCIN HEALTHCARE
BIOCON LTD.
BIOGEN INC.
BIONOW
BIONTECH SE
BIOPHORE INDIA PHARMACEUTICALS PVT LTD
BIOSINT S.P.A.
BIOTECHNICA PHARMA GLOBAL
BIOVIAN
BLANVER FARMOQUIMICA
BOEHRINGER INGELHEIM GMBH
BRAMMER BIO
BRAWN BIOTECH LTD.
BRIGHT PATH LABORATORIES
BRISTOL-MEYERS SQUIBB
CADILA PHARMACEUTICALS LTD.
CARLYLE GROUP (AMRI)
CATALENT INC.
CAYMAN CHEMICAL
CELGENE CORPORATION
CELLTRION HEALTHCARE
CENTURY PHARMACEUTICALS LTD.
CERBIOS - PHARMA S.A.
CFM GROUP (AMSA S.P.A)
CHANGZHOU PHARMACEUTICAL FACTORY
CHEMCON GMBH
CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.
CHONGQING HUAPONT PHARMACEUTICAL CO., LTD.
CIPLA LIMITED
CKD BIO
COBA PHARMA S.L.U
CONSORT MEDICAL PLC.
CORDEN PHARMA INTERNATIONAL GMBH
COSMO PHARMACEUTICALS
CTX LIFE SCIENCES PVT. LTD.
DAIICHI SANKYO COMPANY, LIMITED
DAITO PHARMACEUTICAL CO., LTD.
DALTON PHARMA SERVICES
DCS PHARMA AG
DELPHARM SAS
DISHMAN CARBOGEN AMCIS LIMITED
DIVIS LABORATORIES LTD.
DR. REDDY'S LABORATORIES LTD.
EISAI CO., LTD.
ELI LILLY AND COMPANY
ELUSYS THERAPEUTIC, INC.
EMCURE PHARMACEUTICALS LTD.
ENALTEC LABS PRIVATE LIMITED.
EPRIUS BIOPHARMACEUTICALS INC.
ERCROS S.A
ESTECHPHARMA CO., LTD.
ESTEVE QUÍMICA
EVEREST ORGANICS LIMITED
EVONIK INDUSTRIES AG (EVONIC HEALTHCARE)
F. HOFFMANN-LA ROCHE LTD
FABBRICA ITALIANA SINTETICI S.P.A.
FAREVA S.A
FARMABIOS SPA
FARMHISPANIA GROUP
FERRER GROUP (INTERQUIM, S.A.)
FERRING PHARMACEUTICALS
FLAMMA S.P.A.
FLORENTIS PHARMACEUTICALS PVT., LTD.
FORMOSA LABORATORIES INC.
FRESENIUS SE & CO. KGAA
FUJIFILM CORPORATION
GENEREX BIOTECHNOLOGY CORPERATION
GENTEC PHARMACEUTICAL GROUP S.A
GILEAD SCIENCES, INC.
GLAXOSMITHKLINE PLC
GLENMARK GENERICS LTD.
GNOSIS S.P.A.
GRANULES INDIA LTD.
GVK INDUSTRIES LIMITED (GVK BIOSCIENCE)
HAOYUAN CHEMEXPRESS CO.LTD.
HARBOUR BIOMED
HARMAN FINOCHEM LIMITED
HENI CHEMICAL INDUSTRIES
HERAUES HOLDING GMBH
HETERO LABS LTD.
HONOUR LAB LTD.
HOVIONE
HUVAPHARMA
HYBIO PHARMACEUTICAL CO., LTD.
IBIO INC
ICROM SPA
INABATA FRANCE S.A.S.
INALCO S.P.A.
INDENA S.P.A
INPELLIS INC.
INTAS PHARMACEUTICALS LTD.
JEIL PHARMACEUTICAL CO. LTD.
JOHNSON & JOHNSON
JUBILANT LIFE SCIENCES
KATSURA CHEMICAL CO.,LTD.
KBI BIOPHARMA, INC.
KERN PHARMA, S.L.
KLEOS PHARMA
KONGO YAKUHIN CO., LTD.
KOSHER PHARMACEUTICALS
KYORIN HOLDINGS, INC. (KYORIN PHARMACEUTICAL CO., LTD.)
LANNETT CO. INC.
LAURUS LABS.
LEBSA
LGM PHARMA
LIBBS FARMACÊUTICA
LIPTIS PHARMACEUTICALS USA INC.
LONZA GROUP
LOTUS PHARMACEUTICAL CO., LTD.
LUPIN LIMITED
LUSOCHIMICA S.P.A
MACLEODS PHARMACEUTICAL LTD.
MAGLE CHEMOSWED AB
MALLINCKRODT PHARMACEUTICALS
MEDICHEM S.A
MEGAFINE PHARMA LTD
MEHTA API
MERCK KGAA
METROCHEM API
MICRO LABS LTD.
MINAKEM S.A
MOEHS IBERICA S.L.
MOLCAN CORPORATION
MOREPEN LABORATORIES LTD.
MSN LABORATORIES PVT.LTD.
MVIYES PHARMA VENTURES PRIVATE LIMITED
NATCO PHARMA LTD.
NEOVACS
NEULAND LABORATORIES LTD
NEURAXPHARM ARZNEIMITTEL GMBH
NIFTY LABS PVT LTD.
NORCHIM SAS
NOVARTIS INTERNATIONAL AG
NOVASEP HODLINGS SAS
NOVO NORDISK A/S
NOVOCAP S.A.
NUCLIUS LIFESCIENCES
OFICHEM B.V.
OLAINFARM AS
OLON S.P.A
OPTIMUS PHARMA PRIVATE LTD.
OPTUM, INC.
ORGENESIS INC.
ORION OY (FERMION OY)
OUTLOOK THERAPEUTICS, INC.
PARATEK PHARMACEUTICALS INC.
PERMIRA FUNDS (CAMBREX CORPORATION)
PERRIGO COMPANY PLC
PERSONALIZED STEM CELLS, INC.
PFANSTIEHL INC.
PFIZER INC.
PHARMACEUTICAL INTERNATIONAL INC.
PHARMAZELL GROUP
PHYTON BIOTECH LLC
PIERRE FABRE GROUP
PIRAMAL PHARMA SOLUTIONS
POLPHARMA B2B
PRAJNA GENERICS PVT. LTD.
PRECISE GROUP
PRECISION BIOSCIENCES, INC.
PRINCETON BIOMOLECULAR RESEARCH INC
PROBIOGEN AG
PROZOMIX LIMITED
RAKS PHARMA PVT LTD.
RECIPHARM AB
REGENERON PHARMACEUTICALS, INC.
REINE LIFESCIENCE
REVA PHARMA PVT., LTD.
RINQUE PHARMA S.A
ROCHEM INTERNATIONAL INC.
RPG LIFE SCIENCES LTD.
RXN CHEMICALS PVT. LTD.
SAAMYA BIOTECH (INDIA) LTD.
SAJJALA BIO LABS
SAMSUNG BIOLOGICS CO. LTD.
SANECA PHARMACEUTICALS A.S.
SANOFI S.A.
SCINOPHARM TAIWAN LTD.
SEATTLE GENETICS INC.
SEQENS GROUP
SERENITY PHARMACEUTICALS CORP
SERMONIX PHARMACEUTICALS
SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD.
SHANGHAI HENLIUS BIOTECH, INC.
SHENZHEN HAORUI INDUSTRIAL DEV.
SHILPA MEDICARE LIMITED
SHIONO CHEMICAL CO., LTD.
SHIONOGI & CO. LTD.
SHREEJI PHARMA INTERNATIONAL
SICHUAN CLOVER BIOPHARMACEUTICALS, INC.
SIEGFRIED HOLDINNGS AG
SM BIOMED SDN. BHD
SMILAX LABORATORIES LIMITED
SMS PHARMACEUTICALS LIMITED
SPARK THERAPEUTICS
SRINI PHARMACEUTICALS LTD.
STADA ARZNEIMITTEL AG
STANDARD CHEMICAL & PHARMACEUTICAL CO.
STERLING BIOTECH LTD.
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
SUVEN LIFE SCIENCE LTD
SUZHOU RYWAY BIOTECH
SYMBIOTEC PHARMA LAB PVT., LTD
SYNERGENE ACTIVE INGREDIENTS PVT, LTD.
SYN-TECH CHEM. AND PHARMA.CO., LTD.
TAKEDA PHARMACEUTICAL COMPANY LTD.
TARO PHARMACEUTICAL INDUSTRIES LTD.
TB ALLIANCE
TEMAD CO.
TETRAPHASE PHARMACEUTICAL INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD
THERAPEUTICMD INC.
THERAVANCE BIOPHARMA, INC.
THERMO FISHER SCIENTIFIC
TIGENIX NV
TONIX PHARMACEUTICALS
TORRENT PHARMACEUTICALS, LTD.
TPG BIOTECH
TRENZYME GMBH
TRIMAX BIO SCIENCES (P) LIMITED
UMICORE N.V.
UNICHEM LABORATORIES LTD.
UNION QUIMICO FARMACEUTICA, S.A.
UNIQUE BIOTECH LTD.
USV PRIVATE LTD.
VAISHALI PHARMA LTD.
VERTEX PHARMACEUTICALS
VIATRIS INC. (MYLAN N.V./UPJOHN PFIZER INC.)
VIR BIOTECHNOLOGY, INC.
VIRUJ PHARMACEUTICALS PVT, LTD.
VIVIMED LABS LTD.
WANBURY LTD.
WAVELENGTH PHARMACEUTICALS
WELT CARE LIFESCIENCES PVT., LTD.
WOCKHARDT
WUXI APPTEC (STA PHARMACEUTICAL CO., LTD.)
WUXI BIOLOGICS
XELLIA PHARMACEUTICALS
XIAMEN AMOYTOP BIOTECH CO., LTD.
YABAO PHARMACEUTICAL GROUP CO., LTD.
YUNG ZIP CHEMICAL INDUSTRIAL CO., LTD.
ZAMBON GROUP (ZACH)
ZCL CHEMICALS LTD.
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
ZYDUS CADILA

[Report Description]

Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $364,169.4 million by 2027. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing, and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application, and by geography.
The global API market based on synthesis is further divided into synthetic API, Biotech API, and HPAPI. By synthesis, the synthetic API held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), an increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in the incidence of chronic and age-related diseases, rapid growth in the oncology market, technological advancement like cryogenic and continuous flow manufacturing. Biotech API accounted for the share of xx% in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates, bi or multispecific monoclonal antibodies, and vaccines to contain novel coronavirus infections are few factors driving the biotech API market.
Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for the largest share in 2020 and are expected to grow at a high single digit CAGR from 2020 to 2027. The development of next-generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. The vaccine segment is forecasted to grow at a low teen CAGR from 2020 to 2027 owing to the worldwide demand for novel vaccines to treat the coronavirus diseases which emerged as a global pandemic.
Based on the customer base, the global biotech API is further segmented into biologics and biosimilars. Biologics accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The Biologics market is driven globally due to the adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, and increasing the elderly population. Biosimilars accounted for the share of xx% in 2020 and is expected to grow at an exponential CAGR from 2020 to 2027 owing to patent expiry of biological drugs, low cost compared to biologics, increase in chronic diseases, growing geriatric population, and demand for quality healthcare.
Based on the customer base, the global synthetic API is further divided into branded API and generic API. The Branded API accounted for the largest share in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027. The Generic API is expected to grow at a high single digit CAGR from 2020 to 2027, due to the patent expiry of blockbuster drugs, rising healthcare expenses, and shift towards generic medicines led by government initiatives.
By business type, the global API market is divided into captive API and merchant API. The Captive market held the major share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027. The captive API is further divided into branded captive API and generic captive API. The branded captive API accounted for the largest share in 2020 and is expected to grow at a high single digit CAGR from 2020 to 2027 owing to patent protection of blockbuster drugs. The Merchant API market is further divided into branded merchant API and generic merchant API. The Generic merchant API accounted for the largest share in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment, and cost of API manufacturing are some of the factors driving the Merchant API market.
By therapeutic applications, the global API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculoskeletal disorders, and others such as others such as ophthalmology, autoimmune diseases, ENT, dental, dermatology, and pain management. In the application segment, infectious disease accounted for the largest share in 2020 because of the global-wide rapid spread of COVID-19 and increased incidence of other infectious diseases such as tuberculosis, HIV, pneumonia, influenza, hepatitis, and others. The oncology division is expected to grow at a double digit CAGR from 2020 to 2027 driven mainly by the rising incidence of cancer cases, lifestyle changes, increasing geriatric population, high demand for anti-cancer drugs. Currently, there is a trend towards precision medicine which further boosts the global oncology API market growth.
The global API market by therapeutic application is segmented into synthetic API application, biotech API application, and HPAPI application market. In synthetic API application, infectious disease accounted for the largest share in 2020 and oncology is expected to grow at a high single digit CAGR from 2020 to 2027. Under biotech API and HPAPI, the oncology segmented contributed for the largest share of xx% and xx% in 2020 respectively, and is forecasted to grow at a high single digit CAGR of xx% and xx% from 2020 to 2027.
The active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific, and the Rest of the world (ROW). By geography, North America held the largest share in 2020 due to patent expiration of the major drugs, rising demand for biotech APIs, market entry of biosimilars, increasing scope of highly potent drugs, and increase in the prevalence of chronic diseases such as cancer, cardiac disease, diseases associated with central nervous system, and musculoskeletal disorder coupled with high healthcare expenditure. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2020 to 2027 owing to low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drug demand, increased production capabilities, the presence of a large number of domestic and international players, and concentration of CMO companies.
Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries Ltd (Israel), Sanofi S.A. (France), Thermo Fisher Sceintific Inc. (Patheon N.V, U.S), Divis Laboratories (India), Olon S.p.A (Italy), Pfizer Inc. (U.S.), Permira funds (Cambrex Corporation U.K.), Carlyle Group (AMRI, U.S.), and others.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Rest of North America
• Europe
o Italy
o Germany
o France
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Rest of APAC
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle East and Others


1 EXECUTIVE SUMMARY 28
2 INTRODUCTION 36
2.1 KEY TAKEAWAYS 36
2.2 SCOPE OF THE REPORT 37
2.3 REPORT DESCRIPTION 37
2.4 MARKETS COVERED 41
2.5 STAKEHOLDERS 43
2.6 RESEARCH METHODOLOGY 43
2.6.1 MARKET SIZE ESTIMATION 45
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.6.3 SECONDARY SOURCES 48
2.6.4 PRIMARY SOURCES 49
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 50
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 51
2.6.7 ASSUMPTIONS 52
3 MARKET ANALYSIS 54
3.1 INTRODUCTION 54
3.2 MARKET SEGMENTATION 55
3.3 FACTORS INFLUENCING MARKET 57
3.3.1 DRIVERS AND OPPORTUNITIES 58
3.3.1.1 Increasing incidence and prevalence of chronic diseases 58
3.3.1.2 Adoption of biologics in disease management and increasing regulatory approvals in the past year 60
3.3.1.3 Increasing scope of HPAPI market 62
3.3.1.4 Patent expiration of major drugs 63
3.3.1.5 Increasing trend of outsourcing 64
3.3.1.6 Increase in the geriatric population 65
3.3.2 RESTRAINTS AND THREATS 66
3.3.2.1 Contamination of API 66
3.3.2.2 High cost for manufacturing APIs 67
3.3.2.3 A requirement of highly skilled technicians 68
3.3.2.4 Fierce competition between API players 69
3.3.2.5 Stringent regulatory policies and environmental concerns 70
3.4 REGULATORY AFFAIRS 72
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION 72
3.4.1.1 ISO 9001: 2015 quality management system 73
3.4.1.2 ISO 13408 aseptic processing 73
3.4.1.3 ISO 14644-1 clean room standards 73
3.4.2 U.S. 73
3.4.3 CANADA 76
3.4.4 MEXICO 77
3.4.5 EUROPE 77
3.4.6 CHINA 79
3.4.7 INDIA 80
3.4.8 JAPAN 82
3.4.9 AUSTRALIA 83
3.4.10 SOUTH KOREA 83
3.4.11 LATIN AMERICA 84
3.4.12 MIDDLE EAST 84
3.5 TECHNOLOGICAL ADVANCEMENTS 85
3.5.1 INTRODUCTION 85
3.5.2 AUTOMATION AND CONTROL 85
3.5.3 CONTINUOUS MANUFACTURING 86
3.5.4 CRYOGENIC TECHNOLOGY 88
3.5.5 SINGLE - USE SYSTEM (SUS) 89
3.5.6 MAMMALIAN CELL BASED PRODUCTION 90
3.5.7 CELL FREE BASED APPROACH FOR THE PRODUCTION OF PROTEINS 90
3.5.8 ADVANCEMENTS IN HPAPI MANUFACTURING 91
3.6 PORTER’S FIVE FORCE ANALYSIS 92
3.6.1 THREAT OF NEW ENTRANTS 93
3.6.2 THREAT OF SUBSTITUTES 93
3.6.3 BARGAINING POWER OF SUPPLIERS 94
3.6.4 BARGAINING POWER OF BUYERS 95
3.6.5 COMPETITIVE RIVALRY 95
3.7 SUPPLY CHAIN ANALYSIS 97
3.8 MARKET SHARE ANALYSIS 104
3.9 FDA APPROVED API MANUFACTURING UNITS 107
3.10 PHARMACEUTICAL API PRODUCTION VOLUME 109
3.11 PATENT EXPIRY AND ANDA APPROVALS 117
3.12 DRUG MASTER FILING (DMF) 132
3.13 NOTICE OF INSPECTIONAL OBSERVATIONS (FORM 483) 137
3.14 REPURPOSED DRUGS FOR COVID-19 TREATMENT 139
3.15 ACQUISITION, MERGER, AND EXPANSIONS 143
3.16 COLLABORATION AND AGREEMENT BETWEEN API MANUFACTURERS 156
3.17 SELECTED TOP SELLING API 160
3.18 API MANUFACTURERS REVENUE AND CAPABILITIES TABLE 184
4 API GLOBAL MARKET, BY SYNTHESIS 201
4.1 INTRODUCTION 201
4.2 SYNTHETIC API 204
4.2.1 SYNTHETIC API BY CUSTOMER BASE 207
4.2.1.1 Branded synthetic API 209
4.2.1.2 Generic synthetic API 211
4.3 BIOTECH API 213
4.3.1 INTRODUCTION 213
4.3.1.1 Monoclonal antibodies 218
4.3.1.2 Recombinant proteins 223
4.3.1.3 Vaccines 226
4.3.1.4 Other biotech API (cell and gene therapy) 231
4.3.2 BIOTECH API BY CUSTOMER BASE 236
4.3.2.1 Biologic API 238
4.3.2.2 Biosimilar API 241
4.4 HPAPI 244
4.4.1 HPAPI BY CUSTOMER BASE 247
4.4.1.1 Branded HPAPI 249
4.4.1.2 Generic HPAPI 251
5 API GLOBAL MARKET, BY BUSINESS TYPE 254
5.1 INTRODUCTION 254
5.2 CAPTIVE API BY TYPE 257
5.2.1 BRANDED CAPTIVE API 261
5.2.2 GENERIC CAPTIVE API 263
5.3 MERCHANT API BY TYPE 265
5.3.1 BRANDED MERCHANT API 268
5.3.2 GENERIC MERCHANT API 270
6 API GLOBAL MARKET, BY APPLICATION 272
6.1 INTRODUCTION 272
6.2 INFECTIOUS DISEASES 281
6.3 ONCOLOGY 293
6.4 CARDIOVASCULAR DISEASES 303
6.5 CENTRAL NERVOUS SYSTEM 310
6.6 PULMONARY DISORDERS 317
6.7 GASTROINTESTINAL DISORDERS 323
6.8 ENDOCRINE DISORDERS 329
6.9 METABOLIC DISORDERS 335
6.10 GENITOURINARY DISORDERS 343
6.11 MUSCULOSKELETAL DISORDERS 348
6.12 OTHER APPLICATIONS (ANAESTHASIA, AUTOIMMUNE DISEASES, OPTHALMOLOGY, DENTAL, PAIN MANAGEMENT, GYNAECOLOGY, DERMATOLOGY AND ENT) 354
7 REGIONAL ANALYSIS 361
7.1 INTRODUCTION 361
7.2 NORTH AMERICA 366
7.2.1 U.S. 391
7.2.2 REST OF NORTH AMERICA 401
7.3 EUROPE 410
7.3.1 ITALY 436
7.3.2 GERMANY 444
7.3.3 FRANCE 452
7.3.4 REST OF EUROPE 460
7.4 APAC 469
7.4.1 CHINA 494
7.4.2 JAPAN 504
7.4.3 INDIA 512
7.4.4 REST OF APAC 524
7.5 ROW 533
7.5.1 BRAZIL 556
7.5.2 REST OF LATAM 564
7.5.3 MIDDLE EAST & OTHERS 571
8 COMPETITIVE LANDSCAPE 578
8.1 INTRODUCTION 578
8.2 PRODUCT APPROVALS 579
8.3 AGREEMENTS 590
8.4 EXPANSIONS 598
8.5 COLLABORATIONS 603
8.6 PRODUCT LAUNCH 607
8.7 PARTNERSHIP 610
8.8 ACQUISITIONS 612
8.9 OTHERS 615
9 MAJOR COMPANIES 619
9.1 CARLYLE GROUP (ALBANY MOLECULAR RESEARCH INC) 619
9.1.1 OVERVIEW 619
9.1.2 FINANCIALS 620
9.1.3 PRODUCT PORTFOLIO 620
9.1.4 KEY DEVELOPMENTS 620
9.1.5 BUSINESS STRATEGY 622
9.1.6 SWOT ANALYSIS 623
9.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 624
9.2.1 OVERVIEW 624
9.2.2 FINANCIALS 625
9.2.3 PRODUCT PORTFOLIO 628
9.2.4 KEY DEVELOPMENTS 628
9.2.5 BUSINESS STRATEGY 632
9.2.6 SWOT ANALYSIS 633
9.3 DIVIS LABORATORIES 634
9.3.1 OVERVIEW 634
9.3.2 FINANCIALS 635
9.3.3 PRODUCT PORTFOLIO 637
9.3.4 KEY DEVELOPMENTS 637
9.3.5 BUSINESS STRATEGY 638
9.3.6 SWOT ANALYSIS 639
9.4 LONZA GROUP LTD. 640
9.4.1 OVERVIEW 640
9.4.2 FINANCIALS 641
9.4.3 PRODUCT PORTFOLIO 644
9.4.4 KEY DEVELOPMENTS 644
9.4.5 BUSINESS STRATEGY 649
9.4.6 SWOT ANALYSIS 650
9.5 OLON S.P.A. 651
9.5.1 OVERVIEW 651
9.5.2 FINANCIALS 652
9.5.3 PRODUCT PORTFOLIO 652
9.5.4 KEY DEVELOPMENTS 652
9.5.5 BUSINESS STRATEGY 653
9.5.6 SWOT ANALYSIS 654
9.6 PERMIRA FUNDS (CAMBREX CORPORATION U.K.) 655
9.6.1 OVERVIEW 655
9.6.2 FINANCIALS 656
9.6.3 PRODUCT PORTFOLIO 656
9.6.4 KEY DEVELOPMENTS 657
9.6.5 BUSINESS STRATEGY 659
9.6.6 SWOT ANALYSIS 660
9.7 PFIZER INC. 661
9.7.1 OVERVIEW 661
9.7.2 FINANCIALS 662
9.7.3 PRODUCT PORTFOLIO 665
9.7.4 KEY DEVELOPMENTS 665
9.7.5 BUSINESS STRATEGY 672
9.7.6 SWOT ANALYSIS 673
9.8 SANOFI 674
9.8.1 OVERVIEW 674
9.8.2 FINANCIALS 675
9.8.3 PRODUCT PORTFOLIO 678
9.8.4 KEY DEVELOPMENTS 678
9.8.5 BUSINESS STRATEGY 684
9.8.6 SWOT ANALYSIS 685
9.9 TEVA PHARMACEUTICAL INDUSTRIES LIMITED. 686
9.9.1 OVERVIEW 686
9.9.2 FINANCIALS 687
9.9.3 PRODUCT PORTFOLIO 690
9.9.4 KEY DEVELOPMENTS 691
9.9.5 BUSINESS STRATEGY 693
9.9.6 SWOT ANALYSIS 694
9.10 THERMO FISHER SCIENTIFIC INC 695
9.10.1 OVERVIEW 695
9.10.2 FINANCIALS 696
9.10.3 PRODUCT PORTFOLIO 699
9.10.4 KEY DEVELOPMENTS 699
9.10.5 BUSINESS STRATEGY 701
9.10.6 SWOT ANALYSIS 702

LIST OF FIGURES
FIGURE 1 API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN) 35
FIGURE 2 RESEARCH METHODOLOGY: API GLOBAL MARKET 44
FIGURE 3 API GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 45
FIGURE 4 API GLOBAL MARKET: FORECASTING MODEL 46
FIGURE 5 API GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 6 API GLOBAL MARKET SEGMENTATION 56
FIGURE 7 MARKET DYNAMICS 57
FIGURE 8 API GLOBAL MARKET: PORTER’S ANALYSIS 92
FIGURE 9 API GLOBAL MARKET: SUPPLY CHAIN ANALYSIS 97
FIGURE 10 GLOBAL API MARKET SHARE ANALYSIS, 2020 (%) 104
FIGURE 11 FDA APPROVED GLOBAL API MANUFACTURING LANDSCAPE 108
FIGURE 12 SMALL MOLECULE API PRODUCTION BY APPLICATION (2020), IN-HOUSE V/S CMO (2019 – 2027) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2020) (LITRES) 112
FIGURE 13 GLOBAL TOTAL API AND CMO PRODUCTION (2019 – 2027) (METRIC TONS) 113
FIGURE 14 PATENT EXPIRY OF SMALL MOLECULES (2017-2022) 118
FIGURE 15 PATENT EXPIRY (2017-2022) AND ANDA APPROVALS (2020 -2021), BY APPLICATION SHARE (%) 119
FIGURE 16 API DMF FILED BY COUNTRIES (2020) (NO’S) 135
FIGURE 17 API DMF FILED, BY COMPANY (2020) (NO’S) 136
FIGURE 18 FORM 483 NON-COMPLIANCE, BY COUNTRY (2020) (NO’S) 138
FIGURE 19 API GLOBAL MARKET SHARE, BY SYNTHESIS, BY CUSTOMER BASE AND BIOTECH API BY PRODUCT TYPE (2020) (%) 203
FIGURE 20 BIOTECH API GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020) (%) 216
FIGURE 21 VACCINES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%) 230
FIGURE 22 GENERIC HPAPI GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%) 253
FIGURE 23 API GLOBAL MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API BY TYPE (2020) (%) 256
FIGURE 24 CAPTIVE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%) 260
FIGURE 25 API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%) 274
FIGURE 26 SYNTHETIC API GLOBAL MARKET SHARE, BY APPLICATION (2020) (%), CAGR (%) 276
FIGURE 27 BIOTECH API GLOBAL MARKET SHARE, BY APPLICATION, (2020) (%), CAGR (%) 278
FIGURE 28 HPAPI GLOBAL MARKET SHARE, BY APPLICATION, (2020) %, CAGR (%) 280
FIGURE 29 BIOTECH INFECTIOUS DISEASE API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%) 291
FIGURE 30 METABOLIC DISORDER API GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%) 339
FIGURE 31 API GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%) 364
FIGURE 32 API GLOBAL MARKET SHARE, BY REGION AND BY COUNTRY (2020) (%) 365
FIGURE 33 NORTH AMERICA API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%) 382
FIGURE 34 NORTH AMERICA SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%) 383
FIGURE 35 NORTH AMERICA API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%) 384
FIGURE 36 NORTH AMERICA API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 385
FIGURE 37 NORTH AMERICA SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 386
FIGURE 38 NORTH AMERICA BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 387
FIGURE 39 NORTH AMERICA HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 388
FIGURE 40 NORTH AMERICA API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%) 390
FIGURE 41 U.S. API MARKET REVENUE, BY SYNTHESIS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 396
FIGURE 42 U.S. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 397
FIGURE 43 U.S. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 398
FIGURE 44 U.S. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 399
FIGURE 45 U.S. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 400
FIGURE 46 REST OF N.A. API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 405
FIGURE 47 REST OF N.A. API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 406
FIGURE 48 REST OF N.A. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 407
FIGURE 49 REST OF N.A. BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 408
FIGURE 50 REST OF N.A. HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 409
FIGURE 51 EUROPE API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020) (%) 427
FIGURE 52 EUROPE SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%) 428
FIGURE 53 EUROPE API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%) 429
FIGURE 54 EUROPE API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 430
FIGURE 55 EUROPE SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 431
FIGURE 56 EUROPE BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 432
FIGURE 57 EUROPE HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 433
FIGURE 58 EUROPE API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%) 435
FIGURE 59 ITALY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 439
FIGURE 60 ITALY API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 440
FIGURE 61 ITALY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 441
FIGURE 62 ITALY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 442
FIGURE 63 ITALY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 443
FIGURE 64 GERMANY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 447
FIGURE 65 GERMANY API MARKET REVENUE, BY APPLICATION (2020V/S 2027) ($MN) 448
FIGURE 66 GERMANY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 449
FIGURE 67 GERMANY BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 450
FIGURE 68 GERMANY HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 451
FIGURE 69 FRANCE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 455
FIGURE 70 FRANCE API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 456
FIGURE 71 FRANCE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 457
FIGURE 72 FRANCE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 458
FIGURE 73 FRANCE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 459
FIGURE 74 REST OF EUROPE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 464
FIGURE 75 REST OF EUROPE API MARKET REVENUE, BY APPLICATION (2020 V/S 202) ($MN) 465
FIGURE 76 REST OF EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 466
FIGURE 77 REST OF EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 467
FIGURE 78 REST OF EUROPE HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 468
FIGURE 79 APAC API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY PRODUCT TYPE (2020 V/S 2027) (%) 485
FIGURE 80 APAC SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%) 486
FIGURE 81 APAC API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%) 487
FIGURE 82 APAC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 488
FIGURE 83 APAC SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 489
FIGURE 84 APAC BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 490
FIGURE 85 APAC HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 491
FIGURE 86 REST OF APAC API MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%) 493
FIGURE 87 CHINA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 499
FIGURE 88 CHINA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 500
FIGURE 89 CHINA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN) 501
FIGURE 90 CHINA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 502
FIGURE 91 CHINA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 503
FIGURE 92 JAPAN API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 507
FIGURE 93 JAPAN API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 508
FIGURE 94 JAPAN SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 509
FIGURE 95 JAPAN BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 510
FIGURE 96 JAPAN HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 511
FIGURE 97 INDIA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 519
FIGURE 98 INDIA API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 520
FIGURE 99 INDIA SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 521
FIGURE 100 INDIA BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 522
FIGURE 101 INDIA HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 523
FIGURE 102 REST OF APAC API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 528
FIGURE 103 REST OF APAC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 529
FIGURE 104 REST OF APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 530
FIGURE 105 REST OF APAC BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 531
FIGURE 106 REST OF APAC HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 532
FIGURE 107 ROW API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2020 V/S 2027) (%) 547
FIGURE 108 ROW SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2020 V/S 2027) (%) 548
FIGURE 109 ROW API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2020 V/S 2027) (%) 549
FIGURE 110 ROW API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 550
FIGURE 111 ROW SYNTHETIC API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 551
FIGURE 112 ROW BIOTECH API MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 552
FIGURE 113 ROW HPAPI MARKET SHARE, BY APPLICATION (2020 V/S 2027) (%) 553
FIGURE 114 ROW API SHARE, BY COUNTRY (2020 V/S 2027) (%) 555
FIGURE 115 BRAZIL API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 559
FIGURE 116 BRAZIL API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 560
FIGURE 117 BRAZIL SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 561
FIGURE 118 BRAZIL BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 562
FIGURE 119 BRAZIL HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 563
FIGURE 120 REST OF LATAM API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 566
FIGURE 121 REST OF LATAM API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 567
FIGURE 122 REST OF LATAM SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 568
FIGURE 123 REST OF LATAM BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 569
FIGURE 124 REST OF LATAM HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 570
FIGURE 125 MIDDLE EAST & OTHERS API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY PRODUCT TYPE AND API MARKET, BY BUSINESS TYPE (2020 V/S 2027) ($MN) 573
FIGURE 126 MIDDLE EAST & OTHERS API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 574
FIGURE 127 MIDDLE EAST & OTHERS SYNTHETIC API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 575
FIGURE 128 MIDDLE EAST & OTHERS BIOTECH API MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 576
FIGURE 129 MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN) 577
FIGURE 130 KEY GROWTH STRATEGIES, (2019-2021) 578
FIGURE 131 SWOT: ALBANY MOLECULAR RESEARCH INC 623
FIGURE 132 SWOT: BOEHRINGER INGELHEIM GMBH 633
FIGURE 133 SWOT: DIVIS LABORATORIES 639
FIGURE 134 SWOT: LONZA GROUP 650
FIGURE 135 SWOT: OLON S.P.A 654
FIGURE 136 SWOT: CAMBREX CORPORATION 660
FIGURE 137 SWOT: PFIZER INC. 673
FIGURE 138 SWOT: SANOFI 685
FIGURE 139 SWOT: TEVA PHARMACEUTICAL INDUSTRIES LIMITED 694
FIGURE 140 SWOT: THERMO FISHER SCIENTIFIC 702

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+